GLA and Fabry disease: While Health Canada had granted Notice of Compliance (i.e., market authorization) for agalsidase alfa (Replagal®) and agalsidase beta (Fabrazyme®) for the treatment of Fabry diseases, a subsequent HTA coverage recommendation for the ERTs in 2005 advised to “not cover at that price” [38, 39].